Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Recent News
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
Stock Overview
Symbol
SCYX
Exchange
Nasdaq
Market Cap
43.99m
Last Price
$4.43
52-Week Range
$3.68 - $10.48
07/02/2026 08:00 PM EDT